LGND News and Press, Ligand Pharmaceuticals Incorporated From 11/23/20

Two large pharma partners reach clinical-development milestones with OmniAb-derived antibody programs and Ligand earns $4.5 million in milestone payments CStone Pharmaceuticals announces China NDA submission and data for its OmniAb-derived antibody to treat non-small cell lung...

Captisol-enabled ™ product is stable at room temperature for timely administration at the point of patient care Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U....

Image source: The Motley Fool. Ligand Pharmaceuticals Inc (NASDAQ: LGND) Q3 2020 Earnings Call Oct 30, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Ligand Pharmaceuticals Inc (LGND) Q3 2020 Earnings Call Transcri...

Ligand Pharmaceuticals Incorporated (LGND) Q3 2020 Earnings Conference Call October 30, 2020 8:30 AM ET Company Participants Patrick O'Brien - Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Executive Vice President, Finance & Chief Financial Officer Matt Foehr ...

Ligand Pharmaceuticals ([[LGND]] -3.6%) Q3 results:Revenues: $41.8M (+68.7%); Royalties revenue: $9.0M (-7.9%); Captisol sales: $23.4M (+241.5%); Contract revenue: $9.5M (+15.4%).Net Loss: ($6.7M) (-56.1%); Loss Per Share: ($0.42) (-48.2%); Non-GAAP Net Income: $17.5M (+83.4%); Non-...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2020 Q3 earnings call. For further details see: Ligand Pharmaceuticals Incorporated 2020 Q3 - Results - Earnings Call Presentation

Ligand Pharmaceuticals (LGND): Q3 Non-GAAP EPS of $1.04 beats by $0.06; GAAP EPS of -$0.42 misses by $0.95.Revenue of $41.85M (+68.7% Y/Y) misses by $3.24M.Press Release For further details see: Ligand Pharmaceuticals EPS beats by $0.06, misses on revenue

Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand ...

Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q3 earnings results on Friday, October 30th, before market open.The consensus EPS Estimate is $0.98 (+100.0% Y/Y) and the consensus Revenue Estimate is $45.09M (+81.7% Y/Y).Over the last 2 years, LGND has beaten EPS estimates 100% ...

[[ABBV]], [[AON]], [[AXL]], [[BAH]], [[BR]], [[CBOE]], [[CHTR]], [[CL]], [[CVX]], [[FBP]], [[FLIR]], [[FTS]], [[GT]], [[HON]], [[IPGP]], [[ITT]], [[KKR]], [[LEA]], [[LGND]], [[LHX]], [[LYB]], [[MMP]], [[MO]], [[NVT]], [[NWL]], [[PBI]], [[PEG]], [[PNM]], [[PNW]], [[POR]], [[PQG]], [[PSX]], [[P...